Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Bay­er’s Blue­Rock sub­sidiary says ear­ly da­ta sug­gest its stem cell ther­a­py is safe for pa­tients with Parkin­son’s dis­ease, of­fer­ing the first clin­i­cal proof-of-con­cept al­most four years af­ter Bay­er ac­quired the biotech.

A to­tal of 12 pa­tients re­ceived the ther­a­py, be­m­dane­pro­cel (BRT-DA01), which con­sists of dopamine-pro­duc­ing neu­rons de­rived from em­bry­on­ic hu­man stem cells that are then sur­gi­cal­ly im­plant­ed in­to the brain. The ther­a­py was well-tol­er­at­ed in a Phase I study, Blue­Rock said, with no safe­ty events.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER